Arcus Biosciences, Inc.
NYSE:RCUSBiotechnology
-$0.09 today
- Market cap
- $2.27B
- Beta
- 0.84
- P/E (TTM)
- -8.2
- EPS (TTM)
- -$2.94
Volume 1.97M
Average 1.17M
RCUS Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Arcus Biosciences, Inc.NYSE: RCUS
Revenue · Q2 FY2026 · quarter ended Jun 2026
Revenue declines year over year
Q2 FY2026 revenue of $41M fell 74.4% year over year, behind the -55.3% change in trailing-twelve-month revenue. Sequentially, it rose 141.2% from the prior quarter. Over 3 fiscal years it compounded at +30.2% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 10 analysts of $72.34M (-70.7%) for the fiscal year ending Dec 2026, a slowdown from the -4.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $41M+141.2% QoQ
- Last fiscal yearDec 2025
- $247M-4.3% YoY
- LTMJun 2026
- $117M-55.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -74.4% | -70.8% | +3.5 pp |
| 1 year | -4.3% | -70.7% | -66.4 pp |
| 3-year CAGR | +30.2% | -39.0% | -69.1 pp |
| 5-year CAGR | +30.1% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 247M USD
- Year-over-year change
- -4.3%
- 4-year CAGR
- -10.4%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 247M | -4.3% |
| FY2024 | 2024-12-31 | 258M | +120.5% |
| FY2023 | 2023-12-31 | 117M | +4.5% |
| FY2022 | 2022-12-31 | 112M | -70.8% |
| FY2021 | 2021-12-31 | 383M | — |
Revenue vs competitors
How RCUS compares with its peers on the latest reported figures
- RCUS's LTM Jun 2026 revenue of $117M is the 4th highest of the 9 companies compared; the peer median is $68.59M.
- Its year-over-year change of -55.3% is the lowest of 7, against a peer median of +140.0%.
- Over three fiscal years its annual growth of +30.2% compares with a peer median of +85.5%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $450.91M | +2233.6% | +115.0% | |
| LTM Sep 2026 | $182.57M | +121.2% | +678.6% | |
| LTM Jun 2026 | $156.04M | +158.9% | +31.9% | |
| LTM Jun 2026 | $117M | -55.3% | +30.2% | |
| LTM Jun 2026 | $71.13M | +23220.3% | +241.9% | |
| LTM Mar 2026 | $66.05M | +78.3% | +56.0% | |
| LTM Mar 2026 | $52.04M | -12.8% | +0.2% | |
| LTM Jun 2026 | $3.6M | — | — | |
| LTM Jun 2026 | $0 | — | — | |
| Peer median (excluding RCUS) | $68.59M | +140.0% | +85.5% | |
Competitors are the stored peer set for RCUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 383M | 112M | 117M | 258M | 247M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 10M |
| Gross Profit | 383M | 112M | 117M | 258M | 237M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 96.0% |
| Research & Development | 257M | 288M | 340M | 448M | 523M |
| Selling, General & Admin | 72M | 104M | 117M | 120M | 110M |
| Operating Expenses | 329M | 392M | 457M | 588M | 623M |
| Depreciation & Amortization | 4M | 6M | 8M | 10M | 10M |
| EBITDA | 59M | (258M) | (291M) | (269M) | (335M) |
| EBITDA Margin | 15.4% | -230.4% | -248.7% | -104.3% | -135.6% |
| Operating Income | 54M | (280M) | (340M) | (330M) | (386M) |
| Operating Margin | 14.1% | -250.0% | -290.6% | -127.9% | -156.3% |
| Interest Income | 1M | 16M | 41M | 52M | 41M |
| Interest Expense | 0 | 2M | 2M | 4M | 8M |
| Other Income / Expenses | 1M | 14M | 39M | 47M | 33M |
| Income Before Tax | 55M | (266M) | (301M) | (283M) | (353M) |
| Pre-Tax Margin | 14.4% | -237.5% | -257.3% | -109.7% | -142.9% |
| Income Tax Expense | 2M | 1M | 6M | 1M | 0 |
| Net Income | 53M | (267M) | (307M) | (283M) | (353M) |
| Net Margin | 13.8% | -238.4% | -262.4% | -109.7% | -142.9% |
| EPS (Basic) | 0.76 | (3.71) | (4.15) | (3.14) | (3.29) |
| EPS (Diluted) | 0.71 | (3.71) | (4.15) | (3.14) | (3.29) |
| Weighted Avg Shares | 69.35M | 72M | 74M | 90.1M | 107.4M |
| Weighted Avg Shares (Diluted) | 73.97M | 72M | 74M | 90.1M | 107.4M |
Arcus Biosciences, Inc.
NYSE:RCUS
Intrinsic Alpha fair value
Locked
Current Price
$15.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.